APA

Kruis W., Schreiber S., Theuer D., Brandes J. W., Schütz E., Howaldt S., Krakamp B., Hämling J., Mönnikes H., Koop I., Stolte M., Pallant D. & Ewald U. (20011228). Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. : Gut.

Chicago

Kruis W, Schreiber S, Theuer D, Brandes J W, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D and Ewald U. 20011228. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. : Gut.

Harvard

Kruis W., Schreiber S., Theuer D., Brandes J. W., Schütz E., Howaldt S., Krakamp B., Hämling J., Mönnikes H., Koop I., Stolte M., Pallant D. and Ewald U. (20011228). Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. : Gut.

MLA

Kruis W, Schreiber S, Theuer D, Brandes J W, Schütz E, Howaldt S, Krakamp B, Hämling J, Mönnikes H, Koop I, Stolte M, Pallant D and Ewald U. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. : Gut. 20011228.